List view / Grid view
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
When you think of microscopy for drug discovery, you may picture images of fixed cells or histologically stained sections of biopsies, collected long after a drug has taken effect. Instead, imagine watching drug responses in real time in whole living animals, visualising drug delivery vehicles at nanoscale and removing the…
Drug Target Review's Ria Kakkad spoke with Victoria Goldenshtein at PEGs Europe, about her lab’s novel in vitro library display platform for directed protein evolution called GRIP display – gluing RNA to its proteins.
Cell line development (CLD) is a critical, early step when entering the development phase of a biotherapeutic. Access to specialist skills and experience, either in-house or remotely, and to multiple technologies and equipment can prove invaluable for the timely and successful completion of this stage. Here, Dr Alison Porter addresses…
Drug Target Review’s Taylor Mixides interviews Cellarity's CEO Fabrice Chouraqui about applying Artificial Intelligence (AI) and Machine Learning (ML) to evolving single-cell technologies.
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…
Tomographic phase microscopy in flow cytometry showcases its ability to accurately measure intracellular lipid droplets.
In this article, Drug Target Review's Izzy Wood uncovers the cutting-edge breakthroughs in T cell research that are revolutionising our understanding of the immune system and paving the way for new therapies and treatments.
Dr John Maher discusses the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours.
In the unmet need for effective treatments to alleviate suffering and prevent premature death across the spectrum of genetic diseases, Brent Warner, Poseida Therapeutics, shares that the ability to edit DNA holds hope for patients currently experiencing incurable genetic diseases and has spurred ongoing efforts to develop and improve gene…
Dr David Baram from gene therapy company EmendoBio provides a snapshot of the history of therapeutic genetic engineering.
Come and join us for our monthly series highlighting Women in STEM. We are excited to present the latest edition for June, featuring an exclusive interview with Dr Jo Brewer, Chief Scientific Officer at Adaptimmune. With a remarkable 15-years of experience in cell therapy, Jo's passion for cells has been…
Dr Jakob Krause Habber and Dr Richard Fox will explore the applications of CRISPR in microbiome engineering and how it can be used to overcome the bottleneck of human microbiome research.
In this eBook, explore how cutting-edge imaging modalities can elevate your biomedical research.
27 June 2023 | By
In this eBook, uncover the transformative potential of AI/ML in single-cell technologies and gain insights into disease progression.
